This article provides a transparent description of Mreg_UKR cell products, including manufacture and quality-control processes, using the structure and vocabulary of the 'Minimum Information about Tolerogenic Antigenpresenting Cells' reporting guidelines. This information is intended as a resource for those in the field, as well as a stimulus to develop a new wave of immunoregulatory and tissue-reparative monocyte-derived cell therapies.
Introduction
Administering cells with immunoregulatory function to patients to control unwanted immune reactions is not a new proposition [1] . From the earliest discovery that transferring regulatory cells from tolerant to nontolerant animals could establish tolerance in the recipient, it was suggested that the same principle could be applied therapeutically in man [2] . However, while adoptive transfer became a common experimental procedure, its translation to the clinic met many obstacles, not least the difficulties of identifying and isolating human regulatory cells. Despite the substantial challenges it presents, cellbased immunoregulatory therapies remain an attractive alternative to general immunosuppression for two main reasons. Firstly, cell therapy approaches offer the possibility of inducing antigen-specific immunological nonresponsiveness. Secondly, as peripheral regulation is a self-reinforcing state [3] , it is possible that cell-based immunoregulatory treatments could have very longlived effects, which would not necessarily be limited by the lifespan of the therapeutic cells. Critically, many of the technical challenges of manufacturing pharmaceutical-grade regulatory cell preparations have now been overcome, paving the way for early-phase clinical studies in solid organ transplantation [4] .
When thinking about cell therapies, it is important to draw a distinction between cell types and particular cellbased products composed of those regulatory cell types [5] [6] [7] . Immunoregulatory cell products contain populations of cells that are inescapably heterogeneous in phenotype, function and degree of contamination with other cells. The exact processes used to manufacture a cell product affect these qualities to such an extent that alternative products containing ostensibly similar cell types may have quite different pharmacological properties [8] . Consequently, to compare between cell products, considerable information is needed about their production methods and biological characteristics. Until recently, however, there was no consensus as to what constituted a sufficient description of a cell product, particularly in the case of monocyte-derived regulatory cell-based products. To address this deficiency, Lord and Hilkens spearheaded an initiative through the A FACTT consortium (http://www.afactt.eu) to develop a minimum information model known as the Minimum Information about Tolerogenic Antigen-presenting Cells (MITAP) protocol [9] . MITAP reporting standards demand information in four parts, describing the manufacture of cell products [1] at the start of the production process, [2] during in vitro development, [3] at the end of the production process, and [4] in clinical application (http://w3id.org/ontolink/mitap). There is considerable support for MITAP in the field because it imposes greater transparency, a controlled vocabulary and makes it easier to interpret and integrate published information about regulatory myeloid cells.
Myeloid regulatory cells as therapeutic agents
Peripheral immunological nonreactivity mediated by regulatory T cells is sustained by professional and nonprofessional antigen-presenting cells with suppressor function, including myeloid regulatory cells, regulatory B cells and nonhaematopoietic lineages that express MHC Class II antigens. The contribution of myeloid regulatory cells to induction and maintenance of peripheral tolerance has been especially well studied [10] [11] [12] . Like regulatory T cells, different myeloid regulatory cell populations serve different physiological and pathophysiological purposes [13] . Under normal physiological, noninflammatory conditions, immature DCs and macrophages present self-or other innocuous antigens to T cells in a subimmunogenic context. Recognition of cognate antigen in the absence of costimulation causes effector T cells to die, become anergic or convert into regulatory T cells. Thereby, antigen presentation by unactivated myeloid APCs contributes to the steadystate maintenance of self-tolerance [14] . A second 'class' of myeloid regulatory cell arises as a consequence of persistent stimulation with pro-inflammatory mediators. Such activation-induced suppressor cells presumably serve as counter regulators that prevent auto-destructive inflammatory responses [15] . Activation-induced myeloid regulatory cells are phenotypically diverse and operate through a variety of mechanisms, including production of T-cell-suppressive soluble factors, receptor-mediated killing of effector T cells and the activation-dependent induction of pTregs.
The classification of myeloid regulatory cells as 'immature' or 'activation-induced' suppressor cells can be extended to ex vivo-generated, monocyte-derived cell types being used in cell-based medicinal products (CBMP). Because immature APCs play such a well-studied role in the maintenance of peripheral tolerance, most efforts to develop monocyte-derived regulatory cell products have naturally focused on myeloid regulatory cells in arrested states of immaturity [16] . Diverse anti-inflammatory treatments have been used to render immature monocyte-derived regulatory cells refractory to activation, including generation in the presence of IL-10 (DC10 cells) [17] or rapamycin (Rapa-DCs) [18] , culture with low concentrations of GM-CSF (Tol-DCs) [19] 
Part 1b: source of cell material
Cell donors undergo mononuclear cell apheresis in accordance with a manufacturing authorization issued by Regierung von Oberbayern. Leucapheresis is performed with a Spectra Optia device using the continuous mononuclear cell collection programme according to the following specifications:
1. Anticoagulant (citrate) dilution 1:10 (range from 1:9 to 1:14)
2. Collection time 120-180 min 3.
Inflow rate >55 ml/min 4.
Packing factor 4.5 5.
Collection pump 1 ml/min 6.
Collection preference Haematocrit of 2-3%
Samples of the final apheresis product are taken for in-process quality-control testing. Total leucocyte and monocyte counts are determined by differential cell counting using a Sysmex device (Table 1 ). Sterility controls are performed using the BactAlert system for detection of aerobic and nonaerobic micro-organisms. Criteria for pharmaceutical release of mononuclear apheresates are as follows:
Total monocyte content ≥0.6 9 10 9 2.
Microbiological control Samples dispatched
After sampling for quality-control purposes, leucapheresis products are stored overnight at 22 AE 2°C in the original collection bag with gentle horizontal agitation to prevent precipitation of cells from suspension. The next day, leucapheresis products are transported to a contract pharmaceutical manufacturing facility under temperature-controlled (22 AE 2°C) conditions.
Part 1c: cell separation process

Human Mreg cells arise from isolated CD14
+ monocytes in the absence of other cell types. Mreg_UKR is manufactured from CD14 + monocytes isolated directly from mononuclear cell apheresates using a Clini-MACS TM device and CliniMACS TM CD14 reagent according to the manufacturer's standard operating procedure. Following the separation and washing steps, a sample is taken for assessment of CD14 + monocyte purity and viability by flow cytometry.
CD14 microbeads are paramagnetic particles composed of a low-molecular dextran polymer with a Fe 2+ / Fe 3+ iron oxide/hydroxide core coated with a mouse monoclonal antibody specific for human CD14. Clini-MACS CD14 Reagent is a dark amber, nonviscous solution composed of CD14 microbeads buffered with phosphate-buffered saline (PBS) containing ethylene diamine tetraacetic acid (EDTA) and Poloxamer 188, which are added as stabilizers. CliniMACS CD14 reagent is supplied sterile and endotoxin-free in glass vials. CliniMACS CD14 reagent is a medical device class III (Rule 17, Annex IX) and is CE-certified by T € UV S € UD Product Service GmbH, Munich. It is assessed according to Annex II of the Medical Device Directive 93/42/EEC and fulfils the essential requirements of this Directive. CliniMACS CD14 reagent is certified under EC Design Examination (Certificate No. 07 09 08 31072 025). The conformity of the CliniMACS CD14 reagent according to the Council Directive is ensured and declared by Miltenyi Biotec GmbH.
During Mreg culture, CD14 microbeads are initially bound to the surface of monocytes, but are completely internalized within 150 min [31] . It is well-established that CD14 delivers its ligands into phagosomes of macrophages [32] , so CD14 microbeads are fated to undergo lysosomal degradation through exposure to an acidic environment (~pH 4.8) and proteases. Under these conditions, antibody and dextran are rapidly degraded, whereas iron simply dissolves. Our group has performed experiments to measure the amount of iron retained by Mregs generated from human peripheral blood monocytes after CD14 microbead selection. Iron content was measured by dissolving Mregs in nitric acid and hydrogen peroxide before quantification of iron in solution by inductively coupled plasma mass spectrometry (unpublished results; collaboration with Dr. Amy Managh). Mregs contained up to 1.42 9 10 9 atoms of iron (equivalent to 1.32 9 10 À13 g/cell iron) per cell.
This is~100-fold greater than the normal iron content of a monocyte-derived macrophage, so it appears CD14-selected monocytes sequester iron from microbeads [5] . Here, we summarize our risk assessment for CD14 microbeads and their possible implications for the safety of (ii) Viability: CD14 + monocyte viability is assessed by 7-AAD exclusion in flow cytometry and typically exceeds 95%.
PART 2: differentiation and induction of tolerogenicity
Manufacture of Mreg_UKR is carried out in accordance with current GMP principles for manufacturing sterile medicinal products. The essential culture conditions for Mreg_UKR were established at University Hospital Regensburg (UKR). The GMP-compliant handling steps necessary for producing a sterile cell product under clean room conditions were developed by a contract research organization in Germany. Assays for Mreg_UKR identity, purity and potency were first established at UKR and then transferred to the contract manufacturer. Here, we describe the principles of Mreg_UKR production and quality control; however, some details of the process are proprietory 'know-how'.
Part 2a: preculture conditions
The manufacture of Mreg_UKR products is a continuous process; hence, no formal distinction is made between drug substance and drug product. CD14 + monocytes isolated by CliniMACS are not stored prior to further manipulation. Isolated monocytes are washed with culture medium to remove CliniMACS separation buffer before monocyte density is adjusted to 10 6 cells/ml in culture medium. Samples are then taken for analysis of CD14 expression and cell viability by flow cytometry.
Part 2b: culture conditions (i) Cell numbers: The number of monocytes used for each Mreg_UKR production run depends upon the number of culture vessels to be seeded. A typical production run uses three to eight vessels that are seeded at 180 9 10 6 viable CD14 + monocytes per vessel. Accordingly, total starting cell numbers may vary between 0.54 9 10 9 and 1.44 9 10 9 viable CD14 + monocytes after CliniMACS isolation.
(ii) Cell concentration: CD14 + monocytes are suspended at 10 6 viable cells/ml in culture medium. This suspension is distributed into culture vessels at a density of 2 9 10 6 cells/cm 2 of vessel surface area. (iii) Culture medium: Mreg cells are generated in an RPMI-based medium supplemented with human AB serum, monocyte colony-stimulating factor (M-CSF) and stabilized L-glutamine. On day 6, Mreg cultures are stimulated with IFN-c. No antibiotics are used at any step in Mreg_UKR production. The composition of Mreg_UKR culture medium is given in Table 2 . The particular reagents used for Mreg_UKR manufacture are specified in Table 3 .
Serum for Mreg_UKR manufacture is sourced from a commercial provider in Germany that supplies recalcified plasma-derived sera pooled from at least 20 male donors of blood group AB. The supplier operates according to Directive 2006/17/EC and guidelines for collection of blood and blood compounds and use of blood products (2010) issued by the German Medical Association. Donors are screened for anti-HIV-1/2 antibodies, anti-HCV antibody, HBs antigen and anti-HBc antibody, as well as screening for syphilis using the Treponema pallidum particle agglutination (TPHA) assay. Additionally, collected sera are tested for HIV-1 and HCV by PCR-based methods. Prior to use in Mreg_UKR culture, human serum is heat-inactivated to destroy complement and then stored frozen to prevent degradation. No virus-inactivation steps are performed. Male-only serum is preferred to female serum because it is theoretically less likely to contain anti-HLA antibodies, which may be elicited by pregnancy. Surprisingly, in a recent study, three commercially sourced, male-only human AB serum batches contained measurable amounts of HLA Class I-and Class II-reactive antibodies [33] . Considering these antibodies were diluted by pooling of sera, it seems that one or more of the plasma donors were truly sensitized. Hypothetically, anti-HLA antibodies could affect Mreg development by opsonizing the cells, leading to activation of other FcR-bearing monocytes, or by inappropriately activating monocytes by retrograde signal transduction through MHC molecules themselves [34] . However, in five separate production runs under research or clean room conditions, Mregs were found to develop normally in the presence of donor-specific antibodies. Moreover, these antibodies did not mediate complement-dependent cytotoxicity in conventional cross-match assays. Manufacturers should be aware of the unexpected presence of anti-HLA antibodies in certain commercially sourced human sera, although these antibodies do not appear to affect the quality of Mreg_UKR products.
During manufacturing-process development, M-CSF concentrations in the range 5-100 ng/ml were tested. No consistent effect of M-CSF concentration on cell viability, yield, phenotype or suppressive function was observed. Time-course experiments revealed that M-CSF was consumed or degraded over time in culture, such that cultures with an initial dose of 5 ng/ml M-CSF contained subphysiological concentrations by day 2 of culture, whereas cultures with an initial dose of 25 ng/ml M-CSF maintained concentrations >10 ng/ml throughout the 7-day culture period.
(iv) Culture container: In the current process, proper development of the Mreg phenotype requires that monocytes adhere at least transiently to the surface of a tissue culture vessel. The exact nature of the closed-system culture vessels used for Mreg_UKR is proprietory information.
(v) Culture environment: Cultures are maintained at 37 AE 1°C and buffered against 5 AE 1% CO 2 . The exact nature of the incubation system is proprietory information.
Part 2c: differentiation or tolerization process protocol
Human Mregs derive from CD14 + peripheral blood monocytes when cultured in the presence of M-CSF and high concentrations of heat-inactivated human serum for more than 4 days prior to stimulation with IFN-c. In the current manufacturing process, monocytes are cultivated in Mreg culture medium for 6 days prior to stimulation with 25 ng/ml recombinant human IFN- Table 3 . GMP-grade reagents specified for preparation of Mreg_UKR culture medium. c for a further 18-24 h. On day 7, Mregs are harvested, washed extensively, resuspended in infusion solution and packaged in a transfusion bag. The duration of culture was optimized to achieve a phenotypically homogeneous population of Mregs. IFN-c results in stable upregulation of indoleamine 2,3-dioxygenase (IDO) that confers suppressive activity to Mreg_UKR over a period of >18 h [22] . At harvest, Mregs are detached from vessel surfaces by purely mechanical means according to a proprietory protocol; notably, trypsinization can reduce overall cell yield and viability, whereas other enzyme preparations (e.g. accutase) can alter the cell-surface phenotype of Mreg cells.
Part 2d: antigen
Mreg_UKR is not pulsed with exogenous antigen. For application in the ONEmreg12 trial in kidney transplantation, Mreg_UKR is generated from peripheral blood monocytes collected from a prospective kidney transplant donor and then administered to the intended kidney transplant recipient. In this setting, Mreg_UKR bears allogeneic tissue antigens, which may include MHC Class I and -II antigens, as well as multiple minor antigens.
Part 2e: storage
The Mreg_UKR cell product consists of Mreg cells suspended in 95 ml Ringer's lactate solution plus 5% human albumin at 1.25-7.5 9 10 6 viable Mregs/ml packaged in a gas permeable transfusion bag. In this condition, Mregs remain viable and phenotypically stable for at least 24 h. In the ONEmreg12 trial, the final cell product is normally administered within 6 hours.
PART 3: cells after Part 3a: phenotype (i) Morphology: In culture, Mregs exhibit a distinctive morphology with the cells adopting a tessellating, epithelioid morphology to form almost confluent monolayers. Individual Mregs are large, densely granular cells with a prominent central body and a thin cytoplasmic skirt, which spreads symmetrically over the surface of the culture vessel, reaching diameters of up to 50 lm. Mregs exhibit a single, roughly spheroid nucleus located centrally within the cytoplasm (Fig. 1a) .
(ii) Cell-surface and intracellular markers: To be released as a pharmaceutical product for administration to patients, each batch of Mreg_UKR must conform to 'release specifications' that describe the identity, purity and potency of its constituent cells. In the case of Mreg_UKR, these properties are measured by flow cytometry-based assays according to GMP principles. Markers used for Mreg_UKR release include CD14, CD16, CD80, CD85h, CD86 and CD258 (Fig. 1b) . The release assay for Mreg_UKR potency is based on IDO expression as a surrogate marker of suppressor activity [22] . The exact specifications used for product release are proprietory information.
Riquelme et al. [35] recently reported that dehydrogenase/reductase 9 (DHRS9), a little-studied retinol (ii) Viability: By specification, Mreg_UKR products must contain >75% viable Mregs, as determined by 7-AAD exclusion in flow cytometry; however, cell viability is typically >90%.
PART 4: about the protocol [28, 29] . Under the ONEmreg12 protocol, on day 7 prior to transplantation, patients receive a single dose of donor-derived Mreg_UKR (2.5-7.5 9 10 6 viable Mregs/kg bodyweight) by slow central venous infusion under cover of 500 mg/day mycophenolate mofetil.
Part 4c: relationship between the source organism of the cells and the target organism For the ONEmreg12 trial, Mreg_UKR is produced from monocytes collected from a prospective living-donor kidney transplant donor and administered to the intended kidney transplant recipient. The ONEmreg12 trial protocol stipulates that donor and recipient must have at least one mismatched allele for HLA-A, -B or -DR; therefore, all participants in the ONEmreg12 study are treated with allogeneic cell products. In other clinical indications, Mreg_UKR may be autologous or 3rd-party origin.
Conclusion
This article provides a transparent, technical description of Mreg_UKR products, including the processes used for manufacture and quality control. This article is not a laboratory protocol or standard operating procedure; however, it contains enough information for any skilled person to appreciate the similarities and dissimilarities between Mreg_UKR and other monocyte-derived immunosuppressive cell products [16, [37] [38] [39] [40] . Accordingly, this article should be a useful resource for those in the field [41, 42] , as well as stimulating development of the next generation of immunoregulatory and tissuereparative monocyte-derived cell therapies.
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